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ABSTRACT 
 
Fermentation of milk with lactic acid bacteria causes degradation of milk proteins into 
small peptides, some of which are biologically active and are therefore called 
bioactive peptides. These bioactive peptides can also be formed in the 
gastrointestinal tract during digestion. In the present study, the effects of the L. 
helveticus fermented milk and its two bioactive peptides, isoleucyl-prolyl-proline (IPP) 
and valyl-prolyl-proline (VPP), were studied on bone metabolism in spontaneously 
hypertensive (SHR) and ovariectomised (OVX) rat models, and on osteoblasts and 
osteoclasts in vitro. In addition, the effects of the L. helveticus and 
caseinphosphopeptides (CPP) on calcium metabolism in postmenopausal women 
were studied.  
 
The L. helveticus supported bone mineral density in growing SHR and prevented 
trabecular bone loss by 16% in OVX after the 12-14-week interventions. The L. 
helveticus fermented milk whey increased bone formation of osteoblasts compared to 
normal sour milk whey, suggesting that there are active components formed during L. 
helveticus fermentation. The pure IPP and VPP peptides in water increased bone 
formation in vitro 4-6-fold, but did not have any effect on bone metabolism in vivo. In 
postmenopausal women, the L. helveticus fermented milk increased serum calcium 
concentration and decreased PTH concentration compared to normal sour milk, 
suggesting enhanced calcium absorption after the ingestion of L. helveticus 
fermented milk. Caseinphosphopeptides given in milk did not show any difference on 
the acute changes in calcium metabolism compared to normal milk in 
postmenopausal women. 
 
According to these results, L. helveticus fermented milk supports bone mineral 
density. This effect may be mediated through the bioactive peptides formed during 
fermentation or through increased bioavailability of protein. The bioactive peptides 
increase bone formation in vitro, but not in vivo. It is possible that the IPP and VPP 
peptides are not bioavailable when given in water. Another explanation is that L. 
helveticus fermented milk affects bone through enhanced calcium absorption after 
ingestion of L. helveticus fermented milk, which causes changes in calcium-
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dependent hormones such as PTH and 1,25 dihydroxyvitamin D. The increased 
calcium absorption may be caused by caseinphosphopeptides that could be formed 
in the gastrointestinal tract. 
 
In conclusion, L. helveticus fermented milk supports bone mineral density in animal 
models and increases calcium absorption in postmenopausal women. These results 
encourage further clinical investigations of the use of L. helveticus fermented milk in 
osteoporosis prevention.  
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1 INTRODUCTION 
 
Osteoporosis is defined as a disorder resulting from compromised bone strength 
predisposing to increased fracture risk. The incidence of osteoporosis is increasing 
as the number of old people in the western countries increases.  
 
The ways of preventing osteoporosis are through maximising peak bone mass and 
attenuating bone loss during the aging process. A 5-10% increase in bone mass is 
related to a 25-50% decrease in fracture risk (Heaney et al. 2000). Adequate calcium 
intake has been shown to support bone growth and prevent bone loss during the 
aging process. Milk and milk products provide 75% of calcium intake in western 
countries (Osler et al. 1997). However, the use of milk products has been declining 
over the past decade (Black et al. 2002), thus increasing the risk groups of low-
calcium intake. In epidemiological studies milk consumption has been related to 
higher bone mineral density. In addition to calcium, milk also consists of many other 
nutrients, such as vitamin D, phosphorus and magnesium, that are important for 
bone health.  
 
Caseinphosphopeptides (CPP) formed from milk protein are known to increase 
calcium absorption in vitro by preventing the precipitation of calcium into an insoluble 
form (Sato et al. 1986). However, in human studies caseinphosphopeptides have 
shown inconsistent results (Heaney et al. 1994, Hansen et al. 1997a, Hansen et al. 
1997b). Other bioactive peptides formed from milk protein during food processing or 
in the gastrointestinal tract have not been studied on calcium or bone metabolism. 
During Lactobacillus helveticus fermentation, isoleucyl-prolyl-proline (IPP) and valyl-
prolyl-proline (VPP) peptides are formed, which have been shown to possess 
angiotensin coverting enzyme (ACE)-inhibitory activity (Nakamura et al. 1995b, 
Sipola et al. 2001). ACE inhibition is an effective means of preventing hypertension, 
and according to in vitro studies (Hagiwara et al. 1998, Hatton et al. 1997), ACE-
inhibition could have an impact on bone as well.  
 
 
 9 
   
 
The purpose of the present thesis was to study the effects of L. helveticus fermented 
milk and milk-protein-derived peptides, caseinphosphopeptides, isoleucyl-prolyl-
proline and valyl-prolyl-proline on calcium and bone metabolism in rat, in in vitro and 
in human studies.  
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2 REVIEW OF THE LITERATURE 
 
2.1   PREVENTION OF OSTEOPOROSIS 
 
During growth, bone formation exceeds bone resorption, resulting in bone mass 
accumulation. Peak bone mass is defined as the full genetic potential of the bone 
mass (for review see Heaney et al. 2000). Peak bone mass is reached during the late 
twenties, with different bone sites reaching peak bone mass at different times 
(Bonjour et al. 1991, Matkovic et al. 1994, Teegarden et al. 1995, Weaver et al. 
1999). A high peak bone mass does not inhibit postmenopausal and age-related 
bone loss but it could maintain bone mass above the fracture risk level at which bone 
loss occurs (Weaver et al. 1999). Genetic variation determines 60-70% of bone 
mineral density (for review see Prentice 2001). After achieving peak bone mass, the 
rate of bone formation and resorption remains constant, until later in life, particularly 
after the menopause in women, the rate of bone resorption overtakes bone 
formation, and bone loss occurs. Estrogen deficiency causes alterations in calcium 
absorption and bone metabolism (Reid 1999). This may partly explain bone loss in 
both sexes, although the mechanism of bone loss is not fully understood. 
 
Osteoporosis is a condition in which decreased bone mass and bone strength lead to 
increased fracture risk. Because bone strength cannot be measured in vivo, bone 
mineral density is used to diagnose osteoporosis. Bone mineral density has been 
shown to correlate well with fracture risk (Cummings et al. 1993, Kröger et al. 1995). 
Osteoporosis is defined as a bone mineral density value of 2.5 SD or more below the 
value of young adults (Kanis 2002). The risk factors for osteoporosis are: female 
gender, age, estrogen deficiency, low body weight and smoking (National Institute of 
Health, 2000). The prevention of osteoporosis should include both maximising peak 
bone mass and the prevention of age-related bone loss. 
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Calcium in osteoporosis prevention 
 
The main environmental factors affecting peak bone mass accumulation are nutrition 
and physical activity. Of the nutrients, calcium intake is most often compromised. The 
recommended calcium intake is 1000 mg/d, varying between countries and age 
groups. Low calcium intake is detrimental for bone; however, intake greater than 
1300 mg/d does not increase calcium retention (Weaver 2000). It has been 
suggested that calcium intake accounts for 5-10% of the peak bone mass (Weaver 
2000), which causes a 25-50% difference in hip fracture rate (Heaney et al. 2000). 
Childhood calcium intake correlates with higher bone mineral content in both 
childhood and adulthood (Molgaard et al. 2001, Wang et al. 2003). A 
supplementation of calcium increases bone mineral density in childhood (Johnston et 
al. 1992, Lee et al. 1996, Lloyd et al. 1996) but most often the positive effect is lost 
when the supplementation ceases (Lee et al. 1996). In a study by Bonjour et al. 
(2001), it was found that with milk-extracted calcium, the higher bone mineral density 
remained for 3.5 years after the intervention period (Bonjour et al. 2001).  
 
Calcium intake is associated with higher bone mineral density during the 
perimenopause and with reduced bone loss during the menopause (Suzuki et al. 
1996, Macdonald et al. 2004).  In cohort studies the correlation between calcium 
intake and fracture risk has not been conclusive (Suzuki et al. 1996, Cumming and 
Nevitt 1997, Michaelsson et al. 2003). It is possible that those with higher risk of 
fracture increased their calcium intake, thus making it difficult to draw conclusive 
interpretations of the results. In calcium deficiency, calcium supplementation has 
been shown to reduce fractures (Recker et al. 1996). One meta-analysis concludes 
that calcium intake has a small but significant effect on bone mineral density (Shea et 
al. 2002). This meta-analysis examined the effect of calcium supplementation with 
minimal vitamin D. Since vitamin D deficiency is common in the elderly (Chapuy et al. 
1997), the effect of calcium supplementation could have been greater if the vitamin D 
intake had been adequate. Simultaneous vitamin D and calcium supplementation 
preserves bone mineral density and protects from fractures in the elderly (for review 
see Rodriguez-Martinez and Garcia-Cohen 2002). 
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Pharmacological therapy in bone loss 
 
The most effective methods of protecting against bone loss are the drug therapies 
(for review see Cranney et al. 2002a). Details of different drug therapies on bone loss 
are shown in Table 1. In postmenopausal women hormone replacement therapy 
(HRT) is effective in reducing bone loss at all the sites of the skeleton. In a meta-
analysis, HRT showed a 4-6% difference in the bone mineral density compared to the 
control group (for review see Wells et al. 2002). Adequate intake of calcium has been 
shown to improve the efficacy of HRT (Sirola et al. 2003). Bisphosphonates affect 
bone by reducing the formation of the osteoclastic enzymes that resorb bone. The 
use of bisphosphonates has been followed for 5-10 years. A 5-year use of 
risedronate showed a 5-8% increase in bone mineral density (Sorensen et al. 2003). 
After a 10-year use of alendronate the bone mineral density 5-14% increased 
compared to the placebo (Bone et al. 2004). Selective estrogen receptor modulators 
(SERMs) act as estrogen agonists or antagonists, depending on the target tissue. 
Raloxifene is an estrogen agonist in bone, and increases bone mineral density in the 
spine and the femoral neck by 2-2.5% (for review see Cranney et al. 2002b). 
Calcitonin increases bone mineral density by 3-4% through blocking the activity of 
osteoclasts (for review see Cranney et al. 2002c). Most pharmacological agents in 
the treatment of osteoporosis act against osteoclast activity and bone resorption. A 
new therapy with a parathyroid hormone (PTH) increases bone formation. One 3-
year treatment with PTH showed an increase in bone mineral density of 2.7% in the 
hip and 13% in vertebral bone (Lindsay et al. 1997). Although drug treatments are 
efficient in osteoporosis treatment, they are always accompanied by a risk of side 
effects, such as thromboembolic disease, gastrointestinal adverse effects or even 
cancer, and the duration of therapy is often limited (for review see Delmas 2002) 
 
In conclusion, both maximising peak bone mass and preventing age-related bone 
loss are important ways of preventing osteoporosis. Calcium plays an important role 
in peak bone mass accumulation. In the elderly both calcium and vitamin D intake 
should be secured. During the most dramatic phase of increased bone loss, drug 
therapies are often essential for preventing osteoporosis. 
 13
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2.2   CALCIUM METABOLISM  
 
Calcium is important in the regulatory systems of the body: in cell metabolism, muscle 
contraction, enzyme production and activation, and also in blood coagulation and 
bone mineralisation. The body contains approximately 1200 g of calcium, of which 
99% is stored in bone. Less than one per cent of the calcium in bone is in constant 
interaction with extracellular calcium. Serum calcium is either bound to serum proteins 
(45%) or other ions  (10%) or is in an ionised form (45%). Ionised calcium is the active 
form of calcium and its concentration in serum is tightly regulated (for reviews see 
Bronner et al. 1993, Guyton and Hall 1996). 
 
Calcium absorption at different calcium intakes varies between 20-40%, increasing 
with lower intakes (for reviews see Heaney 1989a, Weaver 1992). Calcium is mainly 
absorbed in the duodenum and the jejunum by a saturable active mechanism, which 
requires 1,25 dihydroxyvitamin D. In the ileum, calcium is passively absorbed 
depending on the concentration of calcium in the intestinal fluid. During growth, 
pregnancy and lactation, calcium absorption increases. With aging, intestinal 
resistance to 1,25 dihydroxyvitamin D occurs (Pattanaungkul et al. 2000), leading to 
impaired calcium absorption (Wishart et al. 2000). This may be partly due to reduced 
levels of estrogen, in particular in women after the menopause (Heaney and Recker 
1986). The unabsorbed calcium is excreted in the feces together with the endogenous 
calcium excreted into the lumen (for review see Gueguen and Pointillart 2000). All the 
excess absorbed calcium that is not stored in the bone is excreted by glomerular 
filtration in the kidneys. From the glomerular filtration more than 95% of calcium is 
reabsorbed.  
 
Calcium bioavailability is an expression of calcium absorption together with the 
utilisation of calcium in bone (for review see Bronner 1993). As almost all calcium 
absorbed in the body is used in bone metabolism, bone calcium content can be 
considered as a measurement of calcium bioavailability, which can be most reliably 
measured from bone after long-term feedings (Poneros-Schneler and Erdman 1989, 
Peterson et al. 1992, 1995, Tsuchita et al. 1993, Gueguen and Pointillart 2000). 
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Regulation of calcium metabolism 
 
Calcium metabolism is regulated mainly by the parathyroid hormone (PTH), by 1,25 
dihydroxyvitamin D and by calcitonin (Figure 1). PTH is excreted from the parathyroid 
glands when ionised calcium concentration falls below a certain limit. PTH sustains 
the concentration of calcium in serum by increasing calcium excretion from bone, 
decreasing calcium excretion in the kidneys and increasing calcium absorption 
indirectly by activating 1,25 dihydroxyvitamin D, which in its turn stimulates the 
formation of a calcium-binding protein necessary for the absorption of calcium. 
Calcium absorption has been shown to vary according to serum vitamin D levels 
(Heaney et al. 2003). Calcitonin is an endogenous hormone with opposite effects from 
those of PTH. It regulates serum calcium levels by increasing urinary calcium 
excretion and reducing calcium absorption and calcium release from bone.   
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Nutritional factors affecting calcium metabolism 
 
Calcium absorption is affected by dietary factors; fibre, phytates and oxalates have 
been shown to inhibit calcium absorption by forming insoluble calcium salts (for review 
see Gueguen and Pointillart 2000). Calcium ingested with a meal increases calcium 
absorption by 10-30% (Heaney et al. 1989b), which may be because of slower gastric 
emptying. Fermentation of milk has also been postulated to increase calcium 
absorption by slowing down the gastrointestinal emptying rate or by increasing soluble 
calcium as a result of increased acidity (Renner et al. 1983, Mahé et al. 1994, Chonan 
et al. 1998). In previous studies fermentation has been shown to increase serum 
ionised calcium and decrease intact PTH levels acutely (Kärkkäinen et al. 1997, 
Talbot et al. 1999), but in studies using isotope methods fermentation did not increase 
calcium absorption (Smith et al. 1985, Recker et al. 1988, Nickel et al. 1996).   
 
Sodium, caffeine, alcohol and excess intake of protein all increase the urinary loss of 
calcium. Proteins tend to increase calcium excretion mainly due to their sulphur-
containing amino acids, which cause acidic conditions. Potassium, on the other hand, 
produces alkaline conditions, and thus decreases the excretion of urinary calcium 
(Lemann et al. 1989). Phosphorus enhances the reabsorption of calcium in the 
glomerus and increases faecal calcium excretion (Whiting et al. 2002), thus the net 
effect of phosphorus on calcium balance is likely to be small.  
 
The effects of nutrients on calcium bioavailability are dependent on the factors 
affecting absorption, but only a limited number of studies have examined the actual 
effect on bioavailability measured as the mineral content of the femur (for review see 
Gueguen and Pointillart 2000, Camara-Martos and Amaro-Lopez 2002). The effect of 
fermentation on calcium bioavailability has been shown to be augmented by cheese 
compared to normal milk (Ghanem and Hussein 1999). However, in the study of 
Delisle et al., yoghurt did not increase calcium bioavailability compared to milk, 
although calcium absorption increased (Delisle et al. 1995). Therefore the effect of 
fermentation on calcium bioavailability remains uncertain. 
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2.3   METHODS OF ASSESSING CALCIUM ABSORPTION 
 
Several methods are available for studying calcium absorption in humans (for review 
see Charles 1992). The balance study determines the net absorption of calcium after 
a calcium load by analysing the calcium excreted in the urine and the feces. The 
method does not make a distinction between endogenously-excreted calcium and 
non-absorbed calcium, thus it is not an accurate method. The isotope balance study 
measures the absorption of labelled calcium, which can be correlated with labelled 
calcium given intravenously. This method measures absolute calcium absorption, and 
is thus the most accurate method available. However, due to the radioactive nature of 
the calcium it is less often used. 
 
Biological markers in the blood and urine can be used to obtain an indirect 
measurement of calcium absorption (Reid et al. 1986, Guillemant et al. 2000a). An 
oral calcium load suppresses PTH concentrations, which can be measured acutely 
(Kärkkäinen et al. 2001). Within two to three hours after the ingestion of calcium, 95% 
of calcium is absorbed (Kärkkäinen et al. 2001). Passive absorption peaks at six hours 
after the ingestion of calcium. A strong correlation exists between the acute intake of 
calcium and urinary calcium excretion, indicating intestinal calcium absorption. This 
method has been commonly used to measure the effect of calcium supplementation 
on calcium metabolism in short-term studies (Reid et al. 1986, Horowitz et al. 1994, 
Guillemant et al. 2000b, Kärkkäinen et al. 2001).  
 
 
2.4   BONE METABOLISM 
 
Bone is composed of an organic matrix (30%) and minerals (70%). Most of the matrix 
is type 1 collagen. In addition, other proteins, such as osteocalcin, osteonectin and 
osteopontin, are also present. The main minerals in bone are calcium and phosphate, 
present in a form of hydroxyapatite. Carbonate, citrate, magnesium, sodium, fluoride 
and strontium are also found in the hydroxyapatite crystals. 
 
 
 19
   
There are two types of bone: cortical and trabecular bone (Figure 2) (for review see 
Baron 1999). Cortical bone is dense and organised in the form of osteons, bone 
structural units which are connected to one another by blood vessels. Trabecular 
bone, which is more metabolically active, is made up of thin trabeculae, which are 
attached to each other, forming a stable network. 
 
 
 
 
 
 
 
 
 
 
trabecular bone 
 
cortical bone 
 
bone marrow 
 
 
 
 
periosteal bone surface 
 
endosteal bone surface 
epiphysis
metaphysis
diaphysis
 
 
Figure 2: The composition and different structural segments of bone. 
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osteoclasts         MLC   osteoblasts     lining cells 
bone                   clearance   formation  bone  mineralisation 
resorption          of bone       of bone 
                            surface       matrix 
Figure 3: The process of bone remodelling. MLC = macrophage-like cells. (Modified 
from Mundy 1999) 
 
The cells that affect bone are osteoblasts, osteoclasts, osteocytes and lining cells, 
each with its own structure and function (for review see Baron 1999). Osteoclasts are 
bone-resorbing cells that differentiate from precursors influenced by hormones and 
several local factors, such as cytokines. The bone-forming cells, the osteoblasts, on 
the other hand, differentiate in the presence of different hormones and growth factors. 
Osteocytes are osteoblasts that are embedded within the new bone. The function of 
osteocytes is not  
clear, although they are the most common cells in bone. It has been suggested that 
they respond to mechanical stress by increasing bone formation. Lining cells are 
osteoblasts that are not in the process of forming bone. 
 
Bone remodelling 
 
Bone remodelling is a process that takes place when old bone is replaced by new, 
allowing the bone to repair microfractures, renew itself, and adapt to the physical 
needs of mechanical support and calcium balance (Figure 3) (for review see Lian et al. 
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1999). Remodelling replaces 2% of cortical bone and 10% of trabecular bone in one 
year. It takes place throughout the skeleton in a remodelling unit, where bone is 
remodelled independently of the other bone remodelling units. Remodelling begins 
with bone resorption, when osteoclasts resorb bone by excreting hydrogen ions which 
dissolve bone minerals and form an optimal environment for the enzymes. The 
enzymes, mainly cathepsins and collagenases, digest the organic matrix. The bone 
resorption process activates the bone formation process of the osteoblasts. The 
mechanism, through which the coupling occurs, is still unknown. The resorbed bone 
surface is covered with macrophage-like cells that adapt the surface so that it is able 
to bind new bone. Osteoblasts synthesise new bone by releasing matrix proteins that 
are mineralised. After new bone is formed, the osteoblasts are calcified to form 
osteocytes. The resorptive phase takes approximately 10 days. Bone formation, on 
the other hand, lasts 3 months.  
 
Regulation of bone remodelling 
 
Remodelling is under the control of both systemic and local hormones (Figure 4). The 
main hormones regulating bone remodelling are PTH and 1,25 hydroxyvitamin D, but 
other hormones, such as calcitonin, glucocorticosteroids, insulin, growth factors, 
thyroid hormones and androgen and estrogen, also affect bone remodelling (for 
review see Mundy 1999, Russell 2001). PTH increases calcium release from bone, 
but it also stimulates the differentiation of osteclasts and activates the preformed 
osteoclasts. 1,25 dihydroxyvitamin D activates mature osteoclasts and thus stimulates 
bone resorption. It is also involved in osteoblastic differentiation and activity. 
Estrogens increase the activation of 1,25 hydroxyvitamin D and the production of 
calcitonin. They also affect osteoclasts directly by decreasing interleukin 1-induced 
osteoclast formation and increasing osteoclast apoptosis (Qu et al. 1998, 1999). 
Calcitonin inhibits osteoclast formation and bone resorption. 
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Nutritional factors affecting bone metabolism 
 
Nutrition plays an essential role in bone health. Milk products, fruit and vegetables 
have been shown to be important for bone growth and the prevention of bone loss 
(Macdonald et al. 2004, Whiting et al. 2004). Since nutrition is a combination of 
several nutrients, the assessment of the effects on bone is complex. Nutrients 
important for bone growth are proteins, vitamins D, C and K, and minerals such as 
calcium and phosphate, and also magnesium, potassium, iron, copper and zinc (for 
review see Heaney et al. 2000).  
 
The role of protein is discussed in Chapter 2.4. In foods, vitamin D is present in two 
different forms depending on the source of the vitamin. Cholecalciferol (D3) is derived 
from animal sources and ergocalciferol (D2) from plant sources. Vitamin D deficiency 
is common, especially during the winter season (Lamberg-Allardt et al. 2001, Chapuy 
et al. 1997). In a meta-analysis, vitamin D treatment has been shown to prevent 
vertebral fractures (Papadimitropoulos et al. 2002). Vitamin C is needed for collagen 
formation (Rowe et al. 1999). Vitamin K is essential for the carboxylation of bone 
matrix proteins (for review see Zittermann 2001). Low vitamin K intake is not 
correlated to bone mineral density but to an increased risk of fracture (Booth et al. 
2000). Phosphate is needed for the mineralisation of bone. Low intakes of phosphate 
may compromise bone mineralisation; however, high phosphate intakes may be 
harmful to bone (for review see Eastell and Lampert 2002). Magnesium is present in 
the hydroxyapatite crystals in bone. Magnesium and potassium have been shown to 
prevent bone loss during the perimenopause and the menopause (New et al. 2000, 
Macdonald et al. 2004). Zinc stimulates the formation of insulin-like growth factor I. 
Zinc deficiency has been correlated to increased risk of fracture (Elmstahl et al. 1998).  
 
Excess intake of certain nutrients may compromise bone health. Serum retinol levels 
correlate positively with fracture risk in men (Michaelsson et al. 2003a), although the 
effect of a dietary intake of vitamin A on fracture risk has shown conflicting results 
(positive: Melhus et al. 1998, Feskanich et al. 2002, negative: Lim et al. 2004). Both 
an excess intake and a deficiency of vitamin A are suggested as being detrimental to 
bone health (Promislow et al. 2002). A low sodium diet decreases bone turnover 
markers compared to a high sodium diet in adults (Evans et al. 1997, Lin et al. 2003) 
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but not in young adults (Ginty et al. 1998). It has been concluded that dietary sodium 
does not have adverse effects on bone in healthy individuals (for review see Cohen 
and Roe 2000). 
 
 
2.5   METHODS OF ASSESSING BONE 
  
Bone mineral density is one of the parameters used in in vivo assessments of bone. It 
has been shown to correlate with the strength of bone (Ammann and Rizzoli 2003). 
The most commonly used technique for measuring bone mineral density is dual 
energy X-ray absorptiometry (DXA) (Mazess et al. 1990). The measurement of bone 
mineral density by DXA determines the areal density of bone (g/cm2) without taking 
into account the size of the bone. A quantitative computed tomography (QCT) is used 
to measure the volumetric bone mineral density (g/cm3). Quantitative ultrasound has 
also been used to assess bone quality. Advanced imaging modalities such as 
microcomputed tomography (microCT), can be applied to examine the three-
dimensional architecture of bone. 
 
Bone turnover can also be assessed in vivo by using biomarkers of bone metabolism 
in serum or urine (for review see Khosla and Kleerekoper 1999). These are mainly 
used to monitor the effect of osteoporosis treatment, but also to study short-term 
effects on bone metabolism. Bone resorption is reflected in collagen degradation 
products both in urine and in serum. Pyridinoline and deoxypyridinoline as well as 
amino- and carboxyterminal telopeptides (NTX, CTX) can be measured from urine. 
The carboxyterminal telopeptide can also be measured from serum (ICTP). The 
tartrate resistant acidic phosphatase 5b, secreted by the osteoclasts, can be 
measured from serum. Bone formation is expressed as either amino- or 
carboxyterminal propeptide type 1 collagen (PINP, PICP). The non-collagenous 
proteins, such as alkaline phosphatase and osteocalcin, are released from osteoblasts 
during bone formation and in the mineralisation process.  
 
From excised bone, its strength, histomorphometry and ash weight can be measured. 
Bone strength reflects the ability of bone to resist mechanical stress. It is determined 
by bone mass, geography and the intrinsic material properties. Changes in the 
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microarchitecture of bone, bone mineral composition, organic matrix and turnover 
rates also affect bone strength (Ammann and Rizzoli 2003). Properties such as 
maximal energy, stiffness, and absorbed energy can be determined by mechanical 
loading until failure occurs. The polar moment of inertia, derived from pQCT 
measurements, reflects the rigidity of the bone, affected by its cross-sectional 
geometry. Bone structure and cellular changes in bone remodelling, such as the bone 
formation rate and the mineral apposition rate, can be measured using static and 
dynamic histomorphometry. Ash weight reflects the mineralisation of bone. Different 
ratios of bone minerals can be measured by analysing the calcium, phosphorus and 
magnesium contents of the ashes. 
 
 
2.6   MILK PROTEIN AND BONE 
 
Correlations with milk consumption and bone 
 
Milk is a good source of several nutrients, such as protein, calcium, phosphate, 
magnesium, potassium and zinc, that are considered important for bone health. In 
epidemiological studies milk consumption in childhood and during adolescence has 
been related to higher bone mineral density in adulthood (Sandler et al. 1985, Hirota 
et al. 1992, Stracke et al. 1993, Murphy et al. 1994, Soroko et al. 1994, Teegarden et 
al. 1995, New et al. 1997, Kalkwarf et al. 2003) (Table 2). This effect has been 
particularly established in white women (Opotowsky and Bilezikian 2003). In cross-
sectional studies milk intake has been shown to correlate to bone mineral density in 
children (Black et al. 2002), in adult men (Egami et al. 2003) and in women (Lacey et 
al. 1991, Tylavsky et al. 1992, Davis et al. 1996, Hawker et al. 2002) (Table 2). 
 
Intervention studies show that milk and milk products increase bone mineral density in 
adolescents, both in girls (Chan et al. 1995, Cadogan et al. 1997, Merrilees et al. 
2000) and in boys (Renner et al. 1998) (Table 3). In pre- and postmenopausal women, 
2-4-year interventions with milk and milk products prevented the bone loss that 
occurred in the control group, who had no dietary intervention, although there was no 
increase in bone mineral density (Baran et al. 1990, Chee et al. 2003). The control 
groups of these intervention studies did not have adequate calcium intake, thus the 
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results of the interventions may be the result of a higher calcium intake by the groups 
receiving milk products. In calcium-controlled studies, calcium supplementation and 
ingestion of dairy products increased bone mineral density in adolescents (Matkovic et 
al. 2004) and reduced bone loss in postmenopausal women (Prince et al. 1995). Dairy 
products have also been shown to increase not only bone mineral density but also 
bone growth (Matkovic et al. 2004). 
 
The effect of milk and milk products on fracture risk has been evaluated in children 
and in women. It has recently been found that children with low milk intake are at 
higher risk of prepubertal bone fractures (Goulding et al. 2004). Higher milk 
consumption by women during the past 12-14 years has been shown to prevent 
fractures in a Japanese population (Fujiwara et al. 2003). In North America 
retrospectively obtained information about childhood milk intake was associated with 
lower fracture risk in females over the age of 50 (Kalkwarf et al. 2003), but milk 
consumed during adulthood did not relate to fracture risk (Feskanich et al. 1997, 
2003). 
 
These results show that the consumption of milk and milk products correlates with 
higher bone mineral density during growth and prevents age-related bone loss. This 
may be the result of a higher calcium intake, in view of the fact that in western 
countries milk contributes 80% of dietary calcium (Fleming and Heimbach 1994). 
However, there are other components in milk that may contribute to the effect on 
bone, and these will be the subject of the present studies.  
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Protein intake and bone  
 
Protein intake is important for bone health. Both inadequate and excess intakes have 
been postulated as having detrimental effects on bone (for reviews see Dawson-
Hughes 2003, Ginty 2003). The effect of protein on bone is dependent on the intake of 
calcium (Meyer et al. 1997). Increase in protein intake causes increased calcium 
excretion through acid production, but this effect is not significant when calcium intake 
is adequate (Heaney 1998, Dawson-Hughes and Harris 2002, Dawson-Hughes et al. 
2004). In addition to the effect on calcium, protein affects bone through insulin-like 
growth factor 1 (IGF-1) (for review see Bonjour et al. 1997), which regulates bone 
growth and bone mineral density (Yakar et al. 2002). Protein supplementation 
increases serum IGF levels (Schürch et al. 1998) and a restriction of protein 
decreases IGF levels (Bourrin et al. 2000). The intake of milk has been associated 
with higher IGF-1 levels, possibly due to the effects of protein (Cadogan et al. 1997, 
Heaney et al. 1999).  
 
Protein intake has been associated with higher bone mineral density in adults 
(Promislow et al. 2002), in postmenopausal women (Kerstetter et al. 2000) and in the 
elderly (Hannan et al. 2000, for review see Bell and Whiting 2002). The effect of 
protein on fracture risk is controversial (negative: Feskanich et al. 1996, Sellmeyer et 
al. 2001, positive: Munger et al. 1999).  
  
To conclude, protein intake is important for bone health. However, without adequate 
calcium intake, a high protein intake can be harmful to bone.  
 
Whey protein and bone 
 
3% of milk is protein, of which 80% is casein and 20%, whey protein. Whey proteins, 
such as alpha lactalbumin and beta lactoglobulin, bind calcium, but this has no effect 
on calcium balance and retention in vivo (Takada et al. 1997a, for review see 
Gueguen and Pointillart 2000). In fact, whey protein has been shown to increase the 
bone-breaking energy of rats compared to casein, by increasing the total amino acid 
content of the femur (Takada et al. 1997a). In growing rats, a whey protein 
supplementation did not make any difference to femoral density, bone mineral content 
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or the biomarkers of bone metabolism after a 7-week intervention (Kelly et al. 2003). 
However, in the same study the whey protein-supplemented casein diet increased 
bone formation after 14 days in a model of ectopic bone formation (Kelly et al. 2003), 
implying that the intervention was too short to demonstrate the effect on bone. These 
results suggest that whey protein does not increase mineral bioavailability but 
supports bone by increasing bone protein, especially bone collagen content. 
 
Whey protein reduces the formation of osteoclasts and their activity (Takada et al. 
1997b). Osteoclast formation measured by multi-nuclei cell formation decreased dose-
dependently with the highest concentration of 1 mg/ml whey. Whey protein has also 
been shown to activate osteoblasts (Takada et al. 1996). 
 
The effect of whey protein on bone could be derived from the basic part of the protein 
(milk basic protein, MBP). Isolated MBP decreases bone deterioration in 
ovariectomised rats (Kato et al. 2000). In human studies short-term ingestion of MBP 
increases radial and calcaneus BMD and decreases bone resorption markers (Aoe et 
al. 2001, Toba et al.  2001, Yamamura et al. 2002). The active component of MBP has 
been found to be kininogen, belonging to high-mobility-group-like proteins (Yamamura 
et al. 1999, 2000). One of the mechanisms by which this active compound affects 
bone is through cystatin C, which inhibits osteoclast activity by decreasing the 
secretion of collagen-digesting cathepsin (Matsuoka et al. 2002).  
 
To summarise the effect of milk on bone, milk consumption has a positive correlation 
with bone mineral density. In addition to its calcium content, milk contains proteins, 
which are beneficial to bone health in the presence of adequate calcium.  
 
 
2.7   MILK-DERIVED BIOACTIVE PEPTIDES ON CALCIUM AND BONE 
METABOLISM 
 
In the gastrointestinal tract, food protein is digested into smaller peptides, some of 
which have physiological effects (for review see Korhonen and Pihlanto 2003). These 
bioactive peptides can be formed by enzymatic hydrolysis with digestive enzymes but 
also by fermentation with starter cultures (for review see Korhonen and Pihlanto 
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2003). In fermentation, the formation of peptides depends on the bacteria used (Matar 
et al. 1996). The active peptides are usually small, consisting of 3-20 amino acid 
residues. Bioactive peptides have been found in many different foods, such as milk, 
eggs, beans, fish and corn (for review see Kitts and Weiler 2003), but milk protein is 
the most important source of bioactive peptides (for review see Korhonen and Pihlanto 
2003).  
 
The bioavailability of peptides most often requires that they should not be digested in 
the gastrointestinal tract. The absorption of small peptides is well known (for review 
see Fricker and Drewe 1996). Peptides can be absorbed through the gastrointestinal 
wall by different mechanisms, such as by passive diffusion through the enterocytes, 
paracellularly, through cytosis or through a carrier (for review see Fricker and Drewe 
1996). Some peptides, such as caseinphosphopeptides, express their activity in the 
gastrointestinal tract without being absorbed. 
 
Bioactive peptides have been shown to have various physiological effects both in vitro 
and in vivo (for reviews see Pihlanto-Leppälä 1999, Korhonen and Pihlanto 2003, 
Meisel and FitzGerald 2003).  Opioid peptides from casein or whey proteins possess 
an affinity to opiate receptors as well as opiate-like effects. They act either as agonists 
or antagonists in the opioid receptors. Opioid peptides influence the nervous system, 
gastrointestinal transit time, nutrient intake and the secretion of insulin and glucagons. 
Antithrombotic peptides derived from casein have been shown to suppress platelet 
aggregation. Immunomodulating peptides stimulate the proliferation of human 
lymphocytes and the phagocytic activities of macrophages. Antimicrobial effects have 
been shown with small whey proteins binding iron, an essential nutrient of micro-
organisms (for review see Clare et al. 2003). Other casein-derived antimicrobial 
peptides have shown anticariogenic effects (for review see Aimutis 2004). The 
antioxidative and hypocholesterolemic effects of bioactive peptides have only recently 
been discovered (for review see Korhonen and Pihlanto 2003). One bioactive peptide 
may have several physiological effects, e.g. casein-derived ?-casomorphin 7 has both 
angiotensin converting enzyme (ACE)-inhibitory effects and opioid-like effects (for 
review see Meisel and Bockelmann 1999). The only milk-derived bioactive peptides 
that have been studied on calcium metabolism are caseinphosphopeptides (CPP) (for 
review see Scholz-Ahrens and Schrezenmeier 2000).  
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Caseinphosphopeptides (CPP) 
 
CPP are a large group of peptides that have a phosphoseryl residue in common. 
Phosphopeptides are formed either from casein by proteolytic enzymes during 
fermentation or in the gastrointestinal tract. CPP increase calcium absorption by 
forming a hydrophobic complex with calcium, thus preventing the formation of 
insoluble calcium phosphates (Meisel and Bockelmann 1999). In vitro studies have 
shown the effects of CPP on calcium absorption by inhibiting the precipitation of 
calcium in the intestine (Sato et al. 1986).  
 
In animal studies, the effect of CPP has produced inconsistent results. In most of the 
studies the CPP have increased calcium absorption (Mykkänen and Wasserman 
1980, Lee et al. 1980, 1983, Kitts et al. 1992, Hirayama et al. 1992, Tsuchita et al. 
1993, 2001, Bennett et al. 2000), but some studies failed to show any effect on 
calcium absorption (Brommage et al. 1991, Kopra et al. 1992). Only one study 
examined the effect of CPP on bone. In this study CPP was found to prevent bone 
loss in ovariectomised rats (Tsuchita et al. 1996).  
 
As early as 1950 Mellander reported the first finding of the effects of CPP in humans 
in his study on rachitic children (Mellander 1950). Increased calcium absorption was 
independent of the effect of vitamin D, suggesting that CPP increase calcium 
absorption in the distal small intestine. In later human studies, the effect of CPP has 
been shown to be influenced by the calcium status of the subjects and by other 
nutrients affecting calcium absorption (Heaney et al. 1994, Hansen et al. 1997a, 
1997b). A CPP preparation increased calcium absorption in women whose calcium 
absorption rate was low (Heaney et al. 1994). The effect of the addition of 1-2 g of 
CPP to different food products has produced conflicting results on calcium absorption. 
Calcium was shown to be more efficiently absorbed from a rice meal compared to 
whole-grain whey (Hansen et al. 1997a); however, in a later study CPP did not show 
any greater effect on calcium absorption from low or high phytate foods (1g) (Hansen 
et al. 1997b).   
 
In conclusion, CPP increase calcium absorption in animal studies but the effect in 
humans is not conclusive.  
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ACE-inhibitory bioactive peptides  
 
ACE is responsible for the generation of angiotensin II (Ang II), a vasopressive, and 
for the inactivation of bradykinin, a vasodepressor. Many milk-derived bioactive 
peptides have shown ACE-inhibitory activity (for review see FitzGerald and Meisel 
2000), though most of these peptides are too large to be absorbed through the 
gastrointestinal tract.  
 
Fermentation of milk with Lactobacillus helveticus (L. helveticus) releases, in 
particular, proline-containing peptides from casein, mainly isoleucyl-prolyl-proline (IPP) 
and valyl-prolyl-proline (VPP), through the action of an X-prolyl dipeptidyl 
aminopeptidase enzyme (Matar et al. 1996, Nakamura et al. 1995a). IPP and VPP 
peptides have been shown to be absorbed through the gastrointestinal tract, as tested 
in vitro (Masuda et al. 1996) and in vivo (Satake et al. 2002), possibly as a result of 
the proline-proline bonds that are resistant to mammalian proteolytic enzymes 
(Vanhoof et al. 1995). IPP and VPP peptides possess ACE-inhibitory activity 
(Nakamura et al. 1995b, Sipola et al. 2001). A long-term feeding with L. helveticus 
fermented milk has been shown to lower blood pressure, indicating an in vivo effect of 
the IPP and VPP peptides, in rats (Sipola et al. 2002) and in humans (Hata et al. 
1996, Seppo et al. 2002, 2003). The peptides given in the fermented milk attenuated 
blood pressure more than the peptides given purely in water, thus there may be other 
mechanisms in L. helveticus fermented milk, such as mineral availability, that affect 
blood pressure. 
  
Polymorphism in ACE causes lower ACE activity, and this has been shown to 
correlate with higher bone mineral density (Perez-Castrillon et al. 2003). Ang II has 
been reported to affect bone by decreasing osteoblast differentiation and increasing 
osteclastic bone resorption (Hagiwara et al. 1998, Hatton et al. 1997). The 
mechanisms through which ACE-inhibitory peptides may affect bone are presented in 
Figure 5. The inhibition of ACE increases the formation of the vascular endothelial 
growth factor (Higgins et al. 2003), which is important for bone formation (Pufe et al. 
2003). On the other hand, Ang II has been reported to increase prostaglandin 
synthesis (Segawa et al. 2003). 
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In addition to converting Ang I to Ang II, ACE inactivates bradykinin. ACE inhibitors 
have even been shown to multiply the activity of bradykinin (Tom et al. 2002). The IPP 
sequence has also been found in bradykinin potentiator peptides (Chi et al. 1985). 
Bradykinin receptors are present in osteoblastic cells (Brechter and Lerner 2002). 
Although bradykinin itself has no effect on osteoblast proliferation (Frost et al. 1999), it 
stimulates prostaglandin synthesis (Goldstein and Wall 1984) and releases nitric oxide 
(Figini et al. 1996), which has an anabolic effect on bone formation (for review see 
van’t Hof and Ralston 2001). Prostaglandin E2 (PGE2) has been shown to affect bone 
by stimulating both osteoblastic differentiation and bone formation (Suda et al. 1996, 
Keila et al. 2001), but also by increasing osteoclast differentiation (Collins and 
Chambers 1992) and bone resorption in vitro (Lader and Flanagan 1998, Suzawa et 
al. 2000). In vivo, PGE2 stimulates bone formation (Suponitzky and Weinreb 1998, Jee 
et al. 1990, Keila et al. 2001).  
 
In conclusion, the IPP and VPP peptides produced during L. helveticus fermentation 
have ACE-inhibitory activity in vivo and in vitro. ACE inhibition can affect bone through 
angiotensin II inhibition or bradykinin activation.  
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  Bradykinin Inactive bradykinin 
  PGE2 
  VEGF 
+ 
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 bone formation  bone resorption 
oooooooooooo 
+ 
+ 
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+ 
- 
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Figure 5: The hypothesis of the effects of bradykinin and ACE inhibition on bone formation and
bone resorption. ACE = angiotensin converting enzyme, Ang I = angiotensin I, Ang II = angiotensin
II, NO = nitric oxide, PGE2 = prostaglandin E 2, VEGF = vascular endothelial growth factor.  
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3  AIMS OF THE STUDY 
 
According to the current literature, milk consumption correlates to higher bone mineral 
density. In addition to calcium, milk contains many nutrients essential for bone health.  
The effect of caseinphosphopeptides on calcium metabolism has been studied in 
humans but the results are not conclusive. The effects of bioactive peptides on bone 
have not been previously studied. The bioactive peptides formed during L. helveticus 
fermentation have been postulated as having ACE-inhibitory activity and as increasing 
mineral absorption. In the present thesis the aim was to explore the effect of L. 
helveticus fermented milk and its bioactive peptides on calcium and bone metabolism. 
The detailed aims were:  
 
1. To investigate the effect of long-term feeding with L. helveticus fermented milk 
and its components on bone parameters in spontaneously hypertensive rats 
with increased bone turnover (Studies I and II) 
 
2. To determine the effect of L. helveticus fermented milk and VPP peptide on 
bone loss in ovariectomised rats (Study III) 
  
3. To specify the effect of L. helveticus fermented milk and its components on 
osteoclast differentiation and bone formation in vitro (Study IV) 
 
4. To evaluate the acute effect of L. helveticus fermented milk and 
caseinphosphopeptides on the markers of calcium metabolism in 
postmenopausal women (Studies V and VI) 
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4 MATERIALS AND METHODS 
 
4.1   ASSESSMENTS OF BONE PARAMETERS IN VIVO (STUDIES I, II, III)  
 
Spontaneously hypertensive rats (SHR; Harlan, Indianapolis, IN, USA) (Studies I, II) 
and ovariectomised normotensive rats (Harlan Sprague Dawley, Indianapolis, IN, 
USA) (Study III) were used to investigate the effect of L. helveticus fermented milk and 
its bioactive peptides on bone parameters following the 12-14-week interventions. The 
body weight-matched rats were divided into different treatment groups (n=10) and 
housed five to a cage (Studies I, II) or in individual cages (Study III) in standard 
experimental laboratory. The consumption of the study products and food was 
monitored throughout the study. The amount of calcium and peptides in the study 
products was adjusted at the beginning of the interventions according to the amount of 
L. helveticus fermented milk consumed by the rats. The protocols were approved by 
the Animal Experimentation Committee of the Institute of Biomedicine, University of 
Helsinki, Finland (Studies I and II) and the Department for Social Welfare and Health 
Services of the Provincial State Office of Western Finland (Study III).   
  
Bone measurements  
 
In the SHR, the bone mineral density and the bone mineral content were measured 
from the right femur by dual-energy X-ray absorptiometry (PIXImus, GE Medical 
Systems LUNAR, Helsinki, Finland) immediately after the intervention. In OVX rats the 
bone mineral density, tissue and bone area measurements and the polar moment of 
inertia were analysed from the proximal end of the right tibia and the tibial diaphysis, 
using peripheral quantitative computed tomography (pQCT) in vivo before the 
operation, four and twelve weeks after the operation. To determine the ash weight, the 
bones were ashed on a metal plate in an electric furnace.  
 
The mechanical properties of the bone were tested from the femoral head-neck 
complex by a cantilever bending test (Studies II, III). The maximal load, energy 
absorbed and stiffness were measured by loading the femoral head with a force 
parallel to the shaft until failure occurred (Peng et al. 1994). 
 
 38
   
Histomorphometrical analyses  
 
For static histomorphometry, the specimens were fixed in increasing concentrations of 
ethanol and embedded in methylmetacrylate. Longitudinal undecalcified sections of 
the tibia were prepared and stained by the Masson-Goldner-trichrome method. The 
trabecular bone volume, trabecular thickness, the number of osteoclasts per tissue 
area and osteoclast surfaces per bone surfaces were determined from the right 
proximal tibia. The bone marrow area and the bone area of the cortical bone were 
evaluated from the tibial diaphysis.  
 
The dynamic histomorphometric parameters of bone formation rate and mineral 
apposition rate were measured from the tibia of labelled animals at 12 weeks, 
following the suggestions of the American Society for Bone and Mineral Research 
(Parfitt 1987). The animals were labelled with tetracycline (20 µg/kg in 0.9% NaCl) 9 
days before termination, and with calcein (20 µg/kg in 0.9% NaCl) 5 days before 
termination.  
 
OsteoMeasure software (Osteometrics Inc., Atlanta, GA, USA) was used for the 
histomorphometric analyses. The analyses were made by a single investigator to 
eliminate the possibility of interindividual variation in the evaluation of the results.  
 
 
4.2   ASSESSMENTS OF BONE FORMATION AND OSTEOCLAST 
DIFFERENTIATION IN VITRO (STUDY VI) 
 
Osteoblast activation and osteoclast differentiation were tested with bone marrow-
derived osteoblast and osteoclast precursor cells from the tibia and femora of 8-12-
week-old female NMRI mice (University of Turku, Turku, Finland). Osteoblast 
activation was tested by culturing the precursor cells for 7 days, following which 
subcultures were prepared. After the subcultures had been cultured for 14 days, the 
deposited calcium was removed with 0.6 M HCl from the bone nodules that had 
formed, and analysed. To determine the osteoclast differentiation, the osteoclast 
precursor cells were cultured in the presence of PTH for 7 days. Osteoclast formation 
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was determined by measuring tartrate resistant acidic phosphatase (TRAP) activity 
from the culture medium at the end of the test (Alatalo et al. 2000).  
 
 
4.3   ASSESSMENT OF CALCIUM METABOLISM IN VIVO (STUDIES IV AND V)  
 
Healthy postmenopausal women who were not taking hormone replacement therapy 
were recruited to the studies, which examined the effect of the L. helveticus fermented 
milk and CPP on calcium absorption acutely (Table 4). The exclusion criteria included 
medication affecting calcium and bone metabolism (Studies V, VI), and the use of 
ACE inhibitors (Study VI). The use of vitamin and mineral supplements was not 
allowed during the studies. 
 
The studies were conducted as double-blind randomised cross-over studies. One 
intervention consisted of two separate days with a one-week washout period in 
between (Figure 6). On the day prior to the study day the subjects consumed a 
restricted amount of milk products (600 mg calcium) in order to control the amount of 
calcium that might affect the results of the study day (Run-in). The product was given 
in randomised order after baseline blood and urinary samples had been collected. 
During the follow-up period of 6-8 hours, standardised meals were served. The effect 
of the products was evaluated by the area under curve (AUC), maximal change and 
change in two hours, of serum ionised calcium, parathyroid hormone (PTH), calcium 
and phosphate and urinary calcium. A three-day food record was analysed by the 
Nutrica program (Social Insurance Institution of Finland, 2000), to estimate the 
habitual calcium intake of the subjects (Study V).  
 
The protocols were approved by the Ethical Committee of the Joint Authority for the 
Hospital District of Helsinki and Uusimaa (Study V) and by the Ethical Committee of 
the University of Helsinki (Study VI). 
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Table 4: The characteristics of the postmenopausal women in studies V and VI. 
  N Age, 
years 
BMI Calcium 
intake, mg/d 
S-D-25, nmol/l 
Study V 20 65 (50-78) 26 (22-31) 1180 ? 400 18-77 
Study VI 9 57 (49-66) 25 (22-29) na na 
 
 
 
 
BMI = body mass index, S-D-25 = Serum 25-hydroxyvitamin D, na = not assessed. 
 
 
 
 
 
                    0           1               2                4             6              8                hours 
  
serum 
urine 
run-in 
 
serum 
urine 
* 
serum 
 
serum
urine 
serum
urine 
serum
urine 
Figure 6: The study day design. After the 24-hour run-in period, the product was given 
after the baseline serum and urine collection. * = study sample. 
 
 
 
4.4   PRODUCTS  
 
The main products used in the different studies are shown in Table 5. The L. 
helveticus milk was produced by fermenting normal milk with L. helveticus 16 H strain 
and supplementing the milk with the solid content of the same milk. As a reference 
product, normal milk and normal sour milk were used (Valio Ltd., Helsinki, Finland). In 
the fermentation of the sour milk, a Lactococcus sp mixed culture was used. 
Caseinphosphopeptide powder, 1000 mg (Phospho Peptide CE 90 CPP, DMV 
International, Veghel, Netherlands) was used as caseinphosphopeptide enrichment. 
The IPP and VPP peptides (Bachem AG, Bubendorf, Switzerland) used in these 
studies were diluted in tap water. Plain tap water was used as a control.  
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Table 5: The main study products.  
 
 
L. 
helveticus 
Sour milk Milk CPP IPP / VPP Water 
Study I X X X   X 
Study II X X   X X 
Study III X    X (VPP) X 
Study IV X X   X  
Study IV X X     
Study VI   X  X   
CPP = caseinphosphopeptides, IPP = isoleucyl-prolyl-proline, VPP = valyl-prolyl-
proline 
 
 
 
In the first SHR study (I) the L. helveticus fermented milk was given in the form of 
whey after the casein was separated by centrifuge. In the cell study the L. helveticus 
and sour milk were filtrated through a 1000 D membrane and diluted in water. The 
concentrations of the IPP and VPP peptides and of calcium chloride were the same as 
in the solutions of the L. helveticus whey. 
 
 
4.5   BIOCHEMICAL ANALYSES 
 
The analyses of the products were carried out at the laboratories of Valio Ltd. (R & D, 
Helsinki, Finland). The mineral composition of all the study products was determined 
by atom absorption spectrometry (AAS). The IPP and VPP contents of the L. 
helveticus fermented milk and the peptide water were determined by a modified 
method of Masuda et al. (Masuda et al. 1996), collecting the peptide fraction by gel 
filtration chromatography (Superdex Peptide HR 10/30 Amersham Pharmacia Biotech, 
Bucks, UK) and analysing it by reversed phase HPLC (Waters Alliance HPLC system, 
Milford, MA, USA) monitored at 214 nm, and quantifying it by using synthesised 
peptides as standards. 
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The mineral contents of the femur were analysed by ICP-MS (inductively coupled 
plasma-mass spectrometry) (Elan 6100, Perkin Elmer, Boston, MA, USA) (Studies I, 
II). 
 
The serum ionised calcium concentration was measured with an ion selective analyser 
(ISE cCa 2+/pH Analyzer 634, Halstead, UK), the serum intact PTH concentration by 
an immunoradiometric assay using Allegro kits (Nichols Institute, San Juan 
Capistrano, CA, USA), and the serum phosphate, serum total calcium, urinary calcium 
and creatinine by routine laboratory methods (Studies V, VI). The serum ICTP was 
analysed using a radioimmunoassay (Risteli et al. 1993) (Study V). 
 
 
4.6   STATISTICAL ANALYSES 
 
Analysis of variance (ANOVA) was used to compare the results between the study 
groups in the animal and cell studies (Studies I-III). One-way ANOVA (Studies I-III) 
was used to compare the L. helveticus group, separately, to the other study groups. 
 
The change in the area under curve (AUC) and maximal change were calculated for 
response variables in the cross-over studies (Studies V, VI). A paired t-test (Study VI) 
and ANOVA for cross-over (Study V) were used to compare the interventions.  
 
The results are expressed as means ± SEM. A value of p<0.05 was considered 
statistically significant.   
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5 RESULTS 
 
5.1   L. HELVETICUS FERMENTED MILK AND BONE PARAMETERS  
 
Effects on bone composition and mechanical properties (Studies I, II, III) 
 
In the first SHR study (I) the L. helveticus fermented milk group showed higher bone 
mineral density in relation to body weight than the water group (0.08 vs 0.07 
mg/cm2/100g, p=0.006) and the sour milk group (0.08 vs 0.07, p=0.01). In the second 
SHR study (II) the L. helveticus fermented milk had higher bone mineral density 
compared to the sour milk group (0.23 vs 0.20 g/cm2, p=0.014) but not to the water 
group (0.23 vs 0.23 mg/cm2, p=0.7). In the histomorphometry the L. helveticus 
showed a 17% higher trabecular thickness (p=0.03) and a 34% higher trabecular bone 
volume (p=0.07) compared to the water group. In the mechanical testing with the 
cantilever bending test there were no differences between the groups.   
 
The ovariectomy caused a 57% loss in the trabecular bone mineral density (p<0.001) 
as well as loss in the cortical bone mineral density (Study III). The treatment with L. 
helveticus fermented milk resulted in a 16% higher trabecular bone mineral density 
(p<0.001) than that of the OVX control group (Table 7). The reduction in cortical bone 
mineral density (1255 vs 1267 mg/cm3, p=0.04) and cortical bone area (5.4 vs 5.8 
mm2, p=0.01) was also attenuated with the L. helveticus fermented milk. In the tibial 
diaphysis the cortical tissue area and bone volume increased in both the pQCT and 
the histomorphometrical measurements. The polar moment of inertia was higher in the 
L. helveticus group, but there was no effect in the mechanical testing of the femoral 
neck. The L. helveticus fermented milk reduced bone turnover by decreasing the bone 
formation rate in the proximal tibia and endocortical surface of the tibial diaphysis, but 
there was no effect on the osteoclasts. 
 
In conclusion, L. helveticus fermented milk shows a clear trend of supporting bone in 
growing rats (Table 6). In OVX rats, L. helveticus fermented milk prevents bone loss in 
the trabecular and cortical bone by decreasing the bone turnover rate (Table 7).  
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Table 6: Summary of the main results of SHR rat studies after a long-term feeding 
with L. helveticus fermented milk and IPP and VPP peptides. (Studies I, II) 
 
 L. helveticus Peptides  
 
BMD   
BMC   
Strength   
Histomorphometry   
 
BMD = bone mineral density, BMC = bone mineral content.    = increased trend 
         = no effect 
 
 
 
 
Body weight gain and the intake of energy and nutrients (Studies I, II, III) 
 
The daily intake of energy and nutrients in the rat studies is shown in Table 8. In SHR 
the body weight gain was higher in the water group than in the L. helveticus group, 
although there was no difference in the energy intake between these two groups. The 
L. helveticus group received the lowest amount of protein and the highest amount of 
calcium (Study I) and phosphorus.  
 
The ovariectomised groups gained more weight than the sham group, as was 
expected. The weight gain was higher in the L. helveticus group than in the OVX 
control group, reflecting the higher energy intake. Fluid consumption was significantly 
higher in the L. helveticus group, which also caused variance in the intake of nutrients, 
mainly of protein and calcium. 
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Table 7: Summary of the effects on OVX of L. helveticus fermented milk and VPP 
peptide (30 mg/l, 60 mg/l) on bone measurements after a long-term feeding (p<0.05). 
 OVX 
vs Sham 
L. helveticus
vs OVX 
VPP 30 / 60 
vs OVX 
Proximal tibia 
   trabecular BMD 
   cortical BMD 
   cortical bone area 
   tissue area 
 
 
 
 
 
 
 
 
 
 
 
 / 
 / 
 / 
 / 
Tibial diaphysis 
   cortical BMD 
   cortical bone area 
   tissue area 
 
 
 
 
 
 
   / 
   / 
   / 
Ash weight     / 
Strength     / 
Static histomorphometry 
   bone volume 
   trabecular thickness 
   diaphysis bone area 
   diaphysis tissue area 
   osteoclast number    
 
 
 
 
 
 
 
 
 
 
 
   / 
   / 
   / 
   / 
   / 
Dynamic histomorphometry 
   proximal BFR 
   proximal MAR 
   endocortical BFR 
   endocortical MAR 
   periosteal BFR 
   periosteal MAR 
 
 
 
 
 
 
 
 
 
 
 
 
   /  
   / 
   / 
   / 
   / 
   / 
OVX = ovariectomised, BMD = bone mineral density, BMC = bone mineral content, 
BFR = bone formation rate, MAR = mineral apposition rate,     = increased effect,      
    = decreased effect,          = no effect. 
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Effects on bone cells (Study IV) 
 
The bone formation rate of the osteoblasts measured with the level of calcium 
accumulated in the formed bone matrix varied between baseline and the different 
treatment groups of L. helveticus (Table 9). L. helveticus whey increased bone 
formation consistently by 20-40% with different solutions. Sour milk whey and calcium 
chloride had no effect on bone formation when the treatment groups were compared 
with baseline.  
 
Osteoclast differentiation did not differ between baseline and the different treatment 
groups with L. helveticus whey and sour milk whey. When the different solutions of L. 
helveticus were compared with baseline, osteoclast differentiation decreased more 
than 25% with all the solutions (p=0.01-0.07). The sour milk whey had similar results, 
although not dose-dependently. 
 
Based on these results, it appears that L. helveticus fermented milk whey promotes 
bone formation in vitro and that this is due to components other than those found in 
sour milk whey. 
 
 
5.2   IPP AND VPP PEPTIDES AND BONE PARAMETERS  
  
Effects on bone composition and mechanical properties (Studies II, III) 
 
In SHR (Study II) the IPP and VPP peptides given in water (70% of the intake in the L. 
helveticus group) had no effect on bone mineral density or mechanical properties 
(Table 6). In the histomorphometry the rats receiving IPP and VPP peptides showed a 
10% higher trabecular thickness than the rats receiving water. There were no changes 
in any of the other histomorphometrical measurements.  
 
In the OVX rats the two doses of VPP in water (80% and 140% of the intake in the L. 
helveticus group) did not protect against bone loss measured as bone mineral density 
and mechanical properties. Nor were there any differences in the histomorphometry. 
(Study III) (Table 7). 
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According to these studies, pure IPP and VPP peptides given in water have no clear 
effects on bone in vivo. 
 
Effects on bone cells (Study IV) 
 
The IPP and VPP peptides increased bone formation in vitro (Table 9) (Study IV). The 
maximal increase with IPP was seen with the 10-6 M concentration (p<0.001). 
However, the highest concentration decreased bone formation (p=0.001). The VPP 
peptide increased bone formation with all the concentrations. The highest, a 6-fold 
increase, was observed with the 10-8 M concentration (p<0.001). The IPP and VPP 
peptides had no effect on osteoclast differentiation.  
 
To summarise, IPP and VPP peptides increase bone formation in vitro, without any 
effect on osteoclast differentiation. 
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Table 9: Summary of the main effects of the different solutions of L. helveticus 
fermented milk whey and sour milk whey and the different concentrations of IPP and 
VPP peptides on bone formation and on the inhibition of osteoclast differentiation 
(p<0.05).  
 Bone formation Osteoclast differentiation 
Dilution L. 
helveticus 
 
IPP VPP L. helveticus Sour milk 
10-10 -     
10-8 -     
10-6      
10-5    - - 
10-4  - -   
10-3  - - - - 
  = increased effect,     = decreased effect,            = no effect,  - = not assessed. 
 
 
 
 
5.3   L. HELVETICUS FERMENTED MILK AND CPP ON CALCIUM METABOLISM 
(STUDIES V AND VI) 
 
Two hours after the L. helveticus fermented milk intake, serum PTH decreased (-14.3 
vs. –8.1 ng/l, p=0.02) and calcium increased (0.04 vs. –0.01 mmol/l, p=0.03) 
compared to the normal sour milk (Study V). During the whole study period PTH 
decreased by 13% (p=0.01) after the L. helveticus fermented milk compared to the 
sour milk. A decreasing trend in the maximal change in serum PTH (-28.8 vs -15.4, 
p=0.07) and an increasing trend in serum calcium (0.09 vs 0.05, p=0.05) was seen 
after the ingestion of the L. helveticus fermented milk. The changes in serum ionised 
calcium, phosphate, ICTP and urinary calcium were similar in the two interventions. 
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Table 10: Summary of the main effects of L. helveticus fermented milk and CPP-
enriched milk on markers of calcium metabolism in postmenopausal women (p<0.05).  
 L. helveticus 
vs sour milk 
CPP milk 
vs milk 
Serum ionised calcium   
Serum PTH   
Serum total calcium   
Urinary calcium   
CPP = caseinphosphopeptide, PTH = parathyroid hormone,    = increased effect,    
    = decreased effect,           = no effect. 
 
 
 
To examine the effect of CPP enrichment on acute changes in calcium metabolism, 
the CPP-enriched milk was compared to normal milk (Study VI). Both milks caused an 
equal reduction in PTH and an equal increase in ionised calcium. The maximal 
changes in ionised calcium, PTH, total calcium, phosphate and urinary calcium were 
similar between the CPP milk and the normal milk groups.  
 
To summarise, the L. helveticus fermented milk showed positive effects on the acute 
response of calcium metabolism in the postmenopausal women. The response to 
CPP-enriched milk was similar to that of  normal milk (Table 10). 
 
 
 
 
 
 
 
 
 51
   
 
6 DISCUSSION  
 
During milk fermentation, bioactive peptides with physiological effects are formed. 
These peptides have been shown to enhance such processes as mineral absorption. 
Nevertheless, there are no prior studies on the effects of bioactive peptides and bone. 
The aim of the present study was to clarify the effect of L. helveticus fermented milk, 
isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) peptides, and casein-
phosphopeptides on the bone metabolism of rats in vivo, on osteoblast and osteoclast 
precursor cells in vitro, and on acute changes in calcium metabolism in man.  
 
 
6.1   L. HELVETICUS FERMENTED MILK AND BONE METABOLISM 
 
In the present study, the effect of L. helveticus fermented milk was assessed on bone 
by using bone cells, and SHR and OVX rat models, as well as acute biochemical 
markers of bone resorption, in postmenopausal women (Table 11).  
 
With rat models it is possible to study the effects of feeding in a controlled setting. 
SHR are a model commonly used in hypertension studies. Adult SHR have been 
shown to have abnormal calcium metabolism (Wright et al. 2000), increased serum 
parathyroid hormone levels and a higher number of osteoclasts in the bone (Merke et 
al. 1989). These abnormalities may be due to decreased serum 1,25 vitamin D (Lucas 
et al. 1986). As a result the SHR develop osteoporosis with advancing age (Izawa et 
al. 1985, Lucas et al. 1986, Merke et al. 1989, Ma et al. 1997). In the present study 
with SHR, bone mineral density was measured only at the end of the study. The 
method used is therefore a cross-sectional observation of a 12-14-week feeding 
effect, and thus could not detect changes as easily as an intervention study in which 
bone mineral density was measured both at baseline and at the end of the study. 
 
 
 
 
 52
   
 
Table 11: Summary of the main results of L. helveticus fermented milk and its 
components on bone in bone cells, animal models and humans. 
SHR = spontaneously hypertensive rats, OVX = ovariectomised rats, BMD = bone 
mineral density, ICTP = bone resorption marker, na = not assessed, IPP = isoleucyl-
prolyl-prolyl, VPP = valyl-prolyl-prolyl,     = increased trend,      = decreased trend,             
       = no effect. 
 L. 
helveticus 
 
IPP and VPP Sour milk 
Bone cells in vitro 
             osteoclast 
differentiation 
             bone formation 
 
 
 
 
 
 
Animal models 
SHR     BMD 
             histomorphometry 
OVX     BMD 
             histomorphometry 
   
 
 
na 
na 
Postmenopausal women 
             ICTP 
 
 
 
na 
 
 
 
 
After ovariectomy, estrogen deficiency induces a dramatic loss of trabecular bone in 
the proximal tibia as a result of increased bone resorption. Cortical bone is not as 
sensitive to estrogen deficiency, although the osteoblasts are reported to increase on 
the endocortical surface. The changes in the bone are similar to those in 
postmenopausal women, therefore the OVX rat is considered a suitable model for 
testing the potential of new drugs to prevent or reverse bone loss in postmenopausal 
osteoporosis (for review see Kalu 1991). 
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In the present study, the bone mineral density in SHR was higher after L. helveticus 
fermented milk compared to normal sour milk. However, there was no significant 
difference between the groups receiving L. helveticus or water. The results of the 
present study were obtained with DXA, which does not take into account the size of 
the bone, thus the higher weight gain of the water group may conceal the real effect of 
the L. helveticus fermented milk. In histomorphometry, the L. helveticus fermented 
milk increased trabecular thickness compared to the water group, indicating that the L. 
helveticus fermented milk had beneficial effects on bone despite the difference in body 
weight.  
 
In OVX rats the treatment with L. helveticus fermented milk maintained a 16% higher 
trabecular bone mineral density in the proximal tibia than in the OVX control group. 
The ash weight of the femur was significantly higher in the L. helveticus group, 
suggesting a larger bone size, which may have caused the rise in the polar moment of 
inertia in both the proximal tibia and the tibial diaphysis. Nevertheless, in the 
mechanical testing there was no difference in the strength measured by maximal load 
and energy from the femoral neck. However, both the cortical tissue area and bone 
volume had increased in the tibial diaphysis, thus the measurement of mechanical 
strength from the diaphysis with a three-point bending test might have given different 
results.  
 
In the OVX study the calcium content of the feed was twice as high as what is 
considered the optimal amount for bone quality (for review see Kalu 1991), thus the 
feed was enough to ensure normal bone growth for the groups. The calcium intake 
was significantly higher in the L. helveticus group than in the OVX control group. A 10-
15 times higher calcium intake has been shown to prevent OVX-induced bone loss 
compared to a lower calcium intake (Geng et al. 2000, Shirai et al. 2002). However, 
studies using a 2-5 times higher calcium intake do not show any effect on bone 
mineral density in OVX rats (Kalu and Orhii 1999, Gala et al. 2001). In the present 
study, the calcium intake was 1.4 times higher in the L. helveticus group than in the 
OVX control group, suggesting that the differences in bone mineral density are not 
dependent on the calcium intake.  
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In human studies the effect of an intervention can be examined with biomarkers of 
bone metabolism acutely (Reid et al. 1986, Horowitz et al. 1994, Rubinacci et al. 1996, 
Guillemant et al. 2000a, 2000b, Scorpacasa et al. 2000). In the present study, both the 
L. helveticus fermented milk and the sour milk caused a decreasing trend in the bone 
resorption marker, ICTP, but there was no significant difference between the two. This 
result accords with previous studies, which showed no effect on ICTP after a 1000 mg 
calcium intake (Sairanen et al. 1994, Kärkkäinen et al. 2001). The negative results are 
disputed by other studies using different markers of bone resorption, in which a 1000 
mg calcium load has been shown to decrease bone resorption measured by urinary 
hydroxyproline and deoxypyridinoline (Reid et al. 1986, Horowitz et al. 1994). Despite 
the difficulties of collecting urine, carboxytelopeptide (CTX) has been shown to be 
more responsive to treatment than ICTP measured from serum (Guillemant et al. 
2000a, 2000b, for review see Leary 2001). Thus the ICTP marker may not have been 
the best biomarker available. According to the results of these studies, the potential 
beneficial effect of L. helveticus fermented milk on bone metabolism in humans cannot 
be confirmed.  
 
The findings of the rat studies were supported by the results of the bone cell culture 
studies, in which the L. helveticus whey increased bone formation. In previous studies, 
milk-derived whey protein has been shown to stimulate osteoblastic cell proliferation 
and to suppress osteoclastic cell formation (Takada et al. 1996, Takada et al. 1997b). 
In our study, both the L. helveticus fermented milk and the sour milk showed some 
trend towards decreasing osteoclast differentiation, which accords with a study with 
whey proteins (Takada et al. 1997b). The effect of whey protein on osteoblast 
stimulation has been postulated as being mediated through the insulin-like growth 
factor I (IGF-I), since the effect on osteoblast cell proliferation was deactivated in the 
presence of both IGF-I and IGF-II antibodies (Takada et al. 1996). In ovariectomised 
rats a low calcium diet supplemented with whey protein has been shown to increase 
the breaking strength of the femoral diaphysis after a 4-week intervention compared to 
a control diet of casein (Takada et al. 1997a). In the present study, the use of sour 
milk as a control rules out the possibility that the mechanism has an effect through the 
components of whey protein. However, there may be differences in the protein 
bioavailability of different milk products. The biological value of the milk protein varies 
depending on the processing, the heat treatment, the starters used and the 
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fermentation conditions (for review see Alm 1980). An amino acid supplementation 
has been shown to increase bone strength and decrease bone loss in ovariectomised 
rats compared to rats receiving casein (Ammann et al. 2002). In L. helveticus 
fermentation the protein is digested mainly into small peptides which are likely to be 
absorbed, while in the fermentation of normal sour milk small peptides are not formed 
to such an extent. Milk protein consists of different growth factors (Cox and Bürk 
1991), although these are not likely to be available in the gastrointestinal tract. 
Nevertheless, protein intake has been shown to increase IGF-1 levels in serum 
(Schürch et al. 1998) and, accordingly, protein restriction depresses IGF-1 levels 
(Bourrin et al. 2000). Thus the effect of L. helveticus fermented milk through IGF-1 
formation is possible.  Other mechanisms through which L. helveticus fermented milk 
may affect bone are the IPP and VPP peptides, as discussed below. 
 
In conclusion, L. helveticus fermented milk has beneficial effects on bone in rats, a 
result which is supported by in vitro studies. But there are so far no conclusive results 
of the effects of L. helveticus fermented milk on bone in humans. 
 
 
6.2   IPP AND VPP PEPTIDES AND BONE METABOLISM 
 
The IPP and VPP peptides are absorbed in the gastrointestinal tract (Nakamura et al. 
1995, Satake et al. 2002), enabling an effect on bone. However, in our study the IPP 
and VPP peptides did not show significant effects on bone mineral density or 
histomorphometry when given in water. These results accord with previous in vivo 
studies with ACE-inhibitory drugs (Stimpel et al. 1995, Ma et al. 1997, Broulik et al. 
2001). Although the present studies were considerably longer than the earlier ones, 
the ACE-inhibitory effect of the IPP and VPP peptides has been reported as being 
clearly weaker compared to that of the pharmacological preparations (Sipola et al. 
2001). However, in previous studies, the IPP and VPP peptides have been shown to 
attenuate the development of blood pressure in rats (Sipola et al. 2001), showing an in 
vivo effect of the peptides. The difference in these results may be due to the difference 
in the site of action for blood pressure and bone. 
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The IPP and VPP peptides increased the bone formation of bone cells when this was 
measured as the accumulation of calcium on bone matrix.  The effect of IPP and VPP 
was significantly higher than that of L. helveticus fermented whey, if one takes into 
account the amount of peptides. There may therefore be components in the L. 
helveticus whey formulation that inhibit the effect of IPP and VPP. In previous studies 
an ACE-inhibitory drug, captopril, showed no effect on osteoblast differentiation when 
it was tested in an osteoblastic cell line MC3T3-E1 (Nishiya and Sugimoto, 2001). It is 
possible that ACE inhibition does not affect the differentiation of osteoblasts, but their 
activity. On the other hand, an ACE inhibitor, enalapril, has been shown to stimulate 
the release of PGE2 from cultured rabbit renomedullary interstitial cells (Zusman 
1981). PGE2 has been shown to increase osteoblast activity in vitro (Keila et al. 2001). 
The in vivo effect of enalapril on PGE2 formation measured from urine is not 
conclusive (Vlasses et al. 1983, Mittman et al. 1985, Broulik et al. 2001). The effect of 
IPP and VPP peptides on prostaglandin formation remains hypothetical. 
 
Another possible reason for the effect of IPP and VPP peptides on bone formation is 
the content of proline. Proline is essential for the formation of the bone matrix. In a 
recent study, the effect of synthesised prolyl-proline (PP), prolyl-valyl-proline (PVP) 
and leucyl-prolyl-proline (LPP) peptides was examined on bone formation (Narva et al. 
unpublished results, 2004). In this study all the peptides were found to activate bone 
formation. These results raise the question as to whether the peptides are digested 
during incubation, and whether the effect of the peptides is dependent on proline 
alone.  
 
To summarise, the IPP and VPP peptides were shown to increase bone formation of 
bone cells in vitro but no effect was seen in in vivo experiments.  
 
 
6.3   L. HELVETICUS FERMENTED MILK, CPP AND CALCIUM METABOLISM  
 
The acute changes in calcium metabolism were measured by serum calcium, ionised 
calcium, parathyroid hormone and urine calcium for six to eight hours after the 
administration of a study milk in postmenopausal women. Calcium absorption 
decreases and bone turnover increases in postmenopausal women, thus these 
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women are a sensible subject group in which to study calcium absorption and bone 
metabolism. Active calcium absorption is known to occur within 2.5 hours and passive 
absorption six hours after small calcium loads (Reid et al. 1986). The acute method 
has been commonly used for measuring the effect of calcium supplementation on 
calcium metabolism acutely (Reid et al. 1986, Kärkkäinen et al. 1997, Guillemant et al. 
2000a, 2000b). The response of calcium metabolism is affected by habitual calcium 
intake, other foods ingested, vitamin D status, and the phase of the menopause 
(Heaney and Recker 1986). To eliminate these effects in the present studies, intra-
individual comparison was used with women with at least one postmenopausal year. 
The effect of other nutrients was excluded by keeping the study meals identical in the 
interventions. The studies were carried out within a period of one month, which 
eliminated the seasonal variation of vitamin D levels.  
 
In the present study, L. helveticus fermented milk reduced serum PTH and increased 
serum calcium concentrations acutely compared to normal fermented milk. In previous 
studies L. helveticus fermented milk has been shown to attenuate the development of 
hypertension in rats (Sipola et al. 2001, Sipola et al. 2002) and in man (Hata et al. 
1996, Seppo et al. 2002, 2003). The effect on blood pressure has been postulated to 
be partly dependent on the ACE-inhibiting peptides, IPP and VPP. However, L. 
helveticus fermented milk prevented the development of hypertension more than IPP 
and VPP peptides in water (Sipola et al. 2001), suggesting that the peptides are less 
biologically available from water or that there are other mechanisms, such as mineral 
bioavailability, through which L. helveticus fermented milk affects blood pressure. In 
the present study, the effect of the L. helveticus fermented milk on the markers of 
calcium absorption in postmenopausal women was confirmed. Although, in the study 
with SHR, the L. helveticus fermented milk did not increase the femoral calcium 
content more than the group receiving normal sour milk, indicating no effect on 
calcium bioavailability. The effect may be explained through CPP formation in the 
intestine. This, however, remains a hypothesis since the formation of CPP after L. 
helveticus ingestion has not been studied. 
 
On the other hand, the markers of calcium metabolism did not differ between the CPP-
enriched milk and normal milk. Both groups received 500 mg of calcium, which 
lowered the level of serum PTH and increased ionised calcium, showing the effect on 
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calcium metabolism. It can therefore be concluded that CPP did not affect calcium 
metabolism acutely compared to normal milk. In previous human studies the effect of 
CPP as part of a rice- or grain-based meal has shown controversial effects on calcium 
absorption (Heaney et al. 1994, Hansen et al. 1997a, Hansen et al. 1997b). The 
present study is the first to investigate the effect of CPP given in a milk formula. In a 
recent study Meisel et al. (2003) examined the amount of CPP in the intestine after the 
ingestion of milk or CPP in water. The study showed that CPP formed in the intestine 
from milk is more effective than preformed CPP given in water. Ileostomy patients 
given 1520 mg of preformed CPP or 250 g of milk were shown to have higher 
amounts of CPP in the ileum after ingestion of milk compared to the preformed CPP. 
According to calculations, 250 g of milk accounts for 120 mg of available CPP (Meisel 
et al. 2003). In the present study, the subjects were given 280 g of milk equivalent of 
approximately 130 mg of CPP or CPP milk enriched with 1000 mg of preformed CPP. 
According to the present study CPP enrichment of milk does not increase calcium 
absorption acutely, possibly because of the inactivation of CPP by the gastrointestinal 
enzymes.  
 
An early study with CPP has suggested that CPP increase passive calcium absorption 
(Mellander, 1950). Vitamin D is essential for the active absorption of calcium, and thus 
the effect of CPP on calcium absorption could be seen more clearly in vitamin D-
deficient subjects. In our studies, the effect of CPP was tested in June, when the 
vitamin D status in Finland is known to be higher than in winter, which might have 
diluted the effect of CPP. The L. helveticus study was conducted in April, when the 
levels of vitamin D were within the normal range (18-77 nmol/l).   
 
Fermentation itself may increase calcium absorption by slowing down the 
gastrointestinal emptying rate due to the difference in the consistence of the milk 
(Mahe et al. 1994). In the present studies the response to CPP-enriched fermented 
milk did not differ from the response to CPP-enriched normal milk. Furthermore, the L. 
helveticus fermented milk showed a greater effect on calcium metabolism than 
normally fermented sour milk, eliminating the possibility that the effect of L. helveticus 
depended only on the fermentation. In previous studies calcium absorption has been 
reported to increase acutely after the ingestion of fermented dairy products, yoghurt 
and cheese, compared to normal milk, when similar calcium loads were used 
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(Kärkkäinen et al. 1997, Talbot et al. 1999). Conversely, in a stable isotope study 
there has been no difference in the absorption of calcium from milk, yoghurt or cheese 
(Recker et al. 1988). The effect of fermentation on calcium bioavailability has been 
assessed in rat bone mineral content with inconclusive results (Delisle et al. 1995, 
Ghanem and Hussein 1999).  
 
In conclusion, L. helveticus fermented milk increases calcium absorption acutely, 
possibly due to CPP formation. However, preformed CPP do not increase calcium 
absorption acutely. After a long-term intervention, calcium bioavailability is not 
enhanced after L. helveticus fermented milk compared to normal sour milk.  
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7 CONCLUSIONS 
 
In the present study, the effects of the L. helveticus fermented milk and the IPP, VPP 
and CPP peptides were studied on calcium and bone metabolism. The following 
conclusions can be drawn from the present study: 
  
1. L. helveticus fermented milk supports bone mineral density in growing rats and 
reduces bone loss in ovariectomised rats. The effect of L. helveticus fermented milk 
may be mediated through the IPP and VPP peptides formed during fermentation or 
the increased bioavailability of milk proteins.  
 
2. The IPP and VPP peptides increase the bone formation of osteoblastic precursor 
cells. However, the IPP and VPP peptides given in water have no effect on bone 
metabolism in vivo in animal models.  
 
3. L. helveticus fermented milk increases calcium absorption in postmenopausal 
women acutely. However, it does not increase calcium bioavailability, measured as 
the calcium content of the bones in rats. 
 
4. Preformed CPP added to a milk solution do not increase calcium absorption acutely 
more than normal milk. It is likely that the gastrointestinal enzymes deactivate the 
preformed CPP, while the milk-derived CPP are formed during gastrointestinal 
digestion. 
 
To summarise, L. helveticus fermented milk increases calcium absorption and 
supports bone mineral density. This study suggests that L. helveticus fermented milk 
may have an additional value as part of a healthy diet in achieving high peak bone 
mass and in preventing bone loss during the aging process. 
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